Ready-to-Use Tagged cDNA Clones
News Jun 01, 2015
The TrueORF product line is a new generation of cDNA clone products that enables expression of the encoded transcript as a tagged protein. This facilitates multiple downstream applications that utilize an anti-tag antibody (Myc-DDK or GFP) including protein detection, protein purification, subcellular localization, and others.
TrueORFs not only provide an instant solution for tagged protein expression but also offer the flexibility that they can be shuttled into multiple destination vectors. AMSBIO TrueORF cDNA clones have verified and guaranteed insert sequences and have been rigorously tested for expression of the target proteins and their tags.
AMSBIO is able to offer genome wide coverage from its greater than 33,000 human, 25,000 mouse and 15,000 rat full-length validated cDNA clones. Provided as 10ug transfection-ready plasmids and driven by CMV promoters, TrueORF cDNA clones produce authentic transcripts without PCR artifacts.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.